Fulltext present in this item

Thumbnail
Fulltext: 171835.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Transaortic Aortic Valve Implantation in 100 Patients: Follow-up to 3 Years
Author(s): Cocchieri, R.; Koh, E.Y.; Wollersheim, L.W.L.M. ; Meregalli, P.G.; Bardai, A.; Bouma, B.J.; Mol, B.A. de
Publication year: 2016
Source: Innovations : Technology and Techniques in Cardiothoracic and Vascular Surgery, vol. 11, iss. 2, (2016), pp. 106-111
ISSN: 1556-9845
DOI: https://doi.org/10.1097/IMI.0000000000000254
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/171835   https://hdl.handle.net/2066/171835

Display more details
Subject: Radboudumc 0: Other Research RIMLS: Radboud Institute for Molecular Life Sciences
Organization: Cardio Thoracic Surgery
Journal title:
Innovations : Technology and Techniques in Cardiothoracic and Vascular Surgery
Volume: vol. 11
Issue: iss. 2
Page start: p. 106
Page end: p. 111
Abstract:
OBJECTIVE: Transaortic aortic valve implantation (TAo-AVI) through the ascending aorta is a novel technique and is used as an alternative in patients with poor femoral access. Although early results have been promising, no midterm data have been published yet. To determine whether this approach is an acceptable treatment option, we analyzed the first 100 cases performed at our institution with a follow-up to 3 years. METHODS: Between July 2011 and January 2015, a total of 100 patients with high-risk or inoperable aortic valve stenosis were treated with TAo-AVI. Preoperative patient data were collected and analyzed retrospectively. All surviving patients were seen for clinical and echocardiographic examination for follow-up. RESULTS: Median follow-up was 15 months. Device success was accomplished in 94 patients (94%). There were no access site complications. The 30-day mortality rate was 9%. Stroke occurred in a total of six patients (6%). Survival at 1-, 2-, and 3 years was 75%, 62%, and 58%, respectively. CONCLUSIONS: Our results show that TAo-AVI is a promising alternative to transapical implantation for treating severe inoperable aortic valve stenosis.

This item appears in the following Collection(s)

Browse

Statistics